1. Home
  2. TOVX vs BX Comparison

TOVX vs BX Comparison

Compare TOVX & BX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Theriva Biologics Inc.

TOVX

Theriva Biologics Inc.

HOLD

Current Price

$0.14

Market Cap

11.1M

Sector

Health Care

ML Signal

HOLD

Logo Blackstone Inc.

BX

Blackstone Inc.

SELL

Current Price

$116.78

Market Cap

94.1B

Sector

Finance

ML Signal

SELL

Company Overview

Basic Information
Metric
TOVX
BX
Founded
2001
1985
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
11.1M
94.1B
IPO Year
2012
2007

Fundamental Metrics

Financial Performance
Metric
TOVX
BX
Price
$0.14
$116.78
Analyst Decision
Buy
Analyst Count
0
24
Target Price
N/A
★ $139.05
AVG Volume (30 Days)
1.1M
★ 4.6M
Earning Date
11-12-2026
10-22-2026
Dividend Yield
N/A
★ 3.94%
EPS Growth
★ 89.07
6.91
EPS
N/A
★ 3.19
Revenue
N/A
★ $14,450,265,000.00
Revenue This Year
N/A
$4.03
Revenue Next Year
N/A
$24.39
P/E Ratio
★ N/A
$37.57
Revenue Growth
N/A
★ 9.22
52 Week Low
$0.14
$101.73
52 Week High
$0.49
$165.14

Technical Indicators

Market Signals
Indicator
TOVX
BX
Relative Strength Index (RSI) 27.65 46.71
Support Level $0.14 $105.57
Resistance Level $0.25 $130.00
Average True Range (ATR) 0.02 3.79
MACD -0.00 0.02
Stochastic Oscillator 7.77 5.17

Price Performance

Historical Comparison
TOVX
BX

About TOVX Theriva Biologics Inc.

Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.

About BX Blackstone Inc.

Blackstone is the world's largest alternative-asset manager with $1.346 trillion in total assets under management, including $961.6 billion in fee-earning assets under management, at the end of June 2026. The company operates with scale in each of its major product lines: private equity (28% of fee-earning AUM and 35% of base management fees), real estate/real assets (29% and 32%), credit and insurance (33% and 25%), and other alternatives (10% and 8%). While the firm primarily serves institutional investors (84% of AUM), it also caters to clients in the high-net-worth channel (16%). Blackstone operates through 25 offices in the Americas (8), Europe and the Middle East (9), and the Asia-Pacific region (8).

Share on Social Networks: